60 results about "Susceptibility testing" patented technology

The invention discloses an in-vitro individualized medicine test method for lung cancer and a culture medium, and belongs to the field of cell biology and pharmacology. The in-vitro individualized medicine test method and the culture medium have the advantages that the culture medium M can be applied to normal epithelial cells and primary tumor cells of human or mammals, accordingly, in-vitro culture systems for tumor cells and para-carcinoma cells of lung cancer patients can be established, and primary cells, with continuous passage and quick proliferation functions, of patient individuals can be obtained; the culture systems can be used for detecting the sensitivity and the safety of medicines or combination groups of the medicines, and accordingly stable, accurate and reliable lung cancer individualized treatment-medicine sensitivity test standard detection process systems can be established; individualized sensitive chemotherapy medicines or compositions screened by the aid of the lung cancer individualized treatment-medicine sensitivity test standard detection process systems can be combined with clinical medicine or relevant subjects, accordingly, clinical individualized treatment schemes can be formulated, and the in-vitro individualized medicine test method and the culture medium can ultimately serve for clinical application.

The invention provides a low-level sweep-frequency current testing system and a testing method which are used for radiated susceptibility test of an electronic system in an HIRF environment. The testing system is established by adopting an equivalent testing method, consists of a low-level sweep-frequency current main testing portion and a large-current injection main testing portion and comprises an electric field calibration device, a large-current testing device and a current injection device. The electric field calibration device is mainly used for measuring a low-level calibration electric field produced by a transmitting antenna, and a measurement result serves as a basis of BCM wiring harness current normalization. The large-current testing device is mainly used for calibrating sensing current on connected wiring harnessed inside the electronic system stimulated by the calibration electric field. The low-level sweep-frequency current testing system and the testing method can finish HIRF radiated susceptibility testing of larger complicated electronic systems including aircrafts, ships, warships and the like, the sweep-frequency electric field required by the testing is low in level, environmental pollution is low, no harm on testing persons is not produced, and the low-level sweep-frequency current testing system is low in cost and can solve the large-power power amplifier embargo problem.

The invention discloses a micro-fluidic chip and application thereof in authentication of pathogene and susceptibility testing. The characteristic that an agar culture-medium has high-temperature digestion and low-temperature solidification is utilized, an authenticating culture medium is placed on the middle layer of the chip, an upper layer chip concentration gradient generator is utilized, and a drug to be studied is introduced; the drug is separated in different culture ponds, multiple pathogene analysis is achieved through the space resolving power of a culture pond array, pathogene authentication is achieved according to the specificity developing result, pathogene quantifying is achieved through real-time developing strength analysis, and the drug susceptibility is determined according to the lowest antibiotic concentration of a developing inhibiting reaction. The micro-fluidic chip is especially suitable for pathogene analysis under the deficient medical resource condition, and has wide application prospects.

The invention discloses a bacteria drug-resistance detection system and an operation method thereof. The system comprises a drug sensitive test inoculation instrument, drug sensitive test image acquisition conversion equipment, a drug sensitivity detection kit and a bacterial strain culture device. A medium is arranged in the drug sensitivity detection kit. The drug sensitive test inoculation instrument is used for inoculating a bacterial strain into the drug sensitivity detection kit. The bacterial strain culture device provides a growth environment for the bacterial strain in the drug sensitivity detection kit. The drug sensitive test image acquisition conversion equipment is used for acquiring and converting images of the bacterial strain in the drug sensitivity detection kit. Management software is arranged in the drug sensitive test image acquisition conversion equipment, and the management software is connected to the network. With combination of online and offline, clinical medication is directly guided. The system meets on-site detection requirements, is convenient for data analysis and decision-making for a farm, a veterinary medicines factory and an administrative department, is suitable for current high-level drug resistance situation in our country, and satisfies the need of quantitative networked monitoring of drug resistance. A broth dilution method and an agar dilution method are both considered. The system meets different requirements of large-scale monitoring and scattered sample detection.

The invention discloses a method for detecting conducted susceptibility, which comprises the following steps: firstly, a conducted susceptibility testing principle model is established; secondly, an ultimate value curve is established; and thirdly, a sensitivity test is carried out by applying the ultimate value curve established in the second step. The invention can completely and accurately check a system level conducted sensitivity testing result, and can obtain the ultimate value curve and a sensitivity ultimate value electrical level, therefore, a system level conducted sensitivity test has an accurate testing basis and a testing standard, and the system level test check is more complete and accurate.

The invention relates to a kit for quickly detecting a drug resistance gene of pneumophila pathogenic bacteria, which comprises a gene chip capable of detecting 24 main drug resistance genes of pneumophila pathogenic bacteria and a reaction system for multiple asymmetric PCR reactions. The 24 drug resistance genes are derived from aminoglycosides, quinolones, extended spectrum beta-lactamases (ESBLs), cephalosporins (AmpC), carbapenems and drug resistance genes with vancomycin resistance and methicillin resistance causing membrane permeability transition. The kit can be used for directly detecting drug resistance genes of pneumophila pathogenic bacteria in clinical samples, is simple and quick to operate, does not need culture or drug sensitive tests, gains valuable time for reasonable application of antibiotics to a great extent, and is worthy of clinical popularization and application.

The invention relates to a method for quickly detecting drug resistance of bacteria. The method comprises the following steps: experimental groups of antibiotics with different concentrations, a positive control group and a negative control group are set, wherein the experimental groups of the antibiotics with the different concentrations refer to experimental groups of adding the antibiotics withthe different concentrations into culture mediums and adding heavy water in subsequent steps, the positive control group refers to the experimental group of adding antibiotics with a concentration of0 into a culture medium and adding heavy water in subsequent steps, and the negative control group refers to the experimental group of adding antibiotics with a concentration of 0 intp a culture medium without adding heavy water in subsequent steps, after incubation is performed, centrifugal washing is performed, samples are subjected to Raman detection, values of C-D/(C-D + C-H) are calculated respectively according to the obtained Raman spectra, a turning point of value decrease of C-D/(C-D + C-H) of the experimental groups of the antibiotics with different concentrations relative to the control groups is taken as a minimum inhibitory concentration of the antibiotics on the bacteria, and the minimum inhibitory concentration is compared with a breakpoint given in a CLSI susceptibility test standard to determine the bacterial sensitivity, intermediation or drug resistance. The method introduces a breakpoint comparison to more accurately give the sensitivity of the bacteria to the antibiotics.

The invention relates to an in-situ rapid detection method for a cell biological process. After absorption, conversion, metabolism or storage for deuterium-containing matters based on active cells, in-situ marking for deuterium in cells can be realized in different stages of the cell biological process, the cells are detected through a Raman spectrum, whether deuterium exists in the cells is identified, and then the biochemical process, cell character or function related information about the cells is obtained. The method can be used for biological and medical fields such as bacterial infection drug susceptibility testing, environmental microbial metabolism and human body cell detection. Compared with the prior art, the method has the potential of detecting the activity and metabolism of the cells for most important biomolecules, and more complex deuteration matters are allowed to be researched and used, including natural products, medicines and a deuterization mixture containing various chemical matters. The method is extremely valuable for function research of the cells under natural conditions of single cell level.

The diagnosis of mycobacteria may be made by growing bacteria from clinical samples in a culture media. The culture medium enables rapid detection of mycobacterial growth by changing its color. It also differentiates mycobacterial growth from contamination by changing to a different color when other species of microorganisms grow. Different types of culture media may be obtained by adding antimicrobial drugs to either obtain a medium selective for mycobacteria or a medium for species differentiation or susceptibility testing of drugs.

The invention relates to the field of drug efficacy screening, and particularly discloses a tumor in-vitro culture method. The tumor in-vitro culture method includes the steps that tumor tissue samples are collected; the tumor tissue samples are treated, and single tumor cells and macrophages are sorted; the single tumor cells are placed in an environment full of hydrogel and then are screened toobtain tumor stem cells; the tumor stem cells and the macrophages are adopted to build a co-culture model to obtain in-vitro culture tumor samples. In this way, the tumor stem cells with high proliferation and differentiation capabilities can be screened out in vitro, therefore, the tumor stem cells are implanted into the animal body, the tumor formation time can be greatly shortened, the tumor formation rate is increased, and then susceptibility testing is conducted; therefore, the progress of susceptibility testing is speeded up, and time for treating patients is bought.

System and methods for performing EMI susceptibility testing of a device is disclosed. A system may include an EMI generation unit that includes a plurality of EMI generating devices, where each EMI generating device generates EMI having substantially similar characteristics relative to EMI generated by other EMI generating devices in the system. Each EMI generating device is controlled by a controller that is configured to emulate at least partly a live cellular network.

A system for identification of bacterial cells in free solution in a sample. A sample handler is adapted to position the sample. A light source illuminates a large volume of the sample. An imager is located to receive light scattered from the sample. A computer it is coupled to receive data transmitted from the imager. A controller is coupled to send control signals to the sample handler and the computer. The imager processes the scattered light to form images of the bacteria and transmits bacteria image information to the computer, wherein the bacteria image information includes intensity values and position data for the bacteria images from which the computer determines the presence of bacteria.

The invention provides a method and a system for identifying bacteria and analyzing drug sensitivity, relating to the technical field of medical treatment reagent type detection. Through digital and automatic comparative analysis, a required result is obtained. Compared with the prior art, the invention provides a system for automatically identifying bacteria/experimenting drug sensitivity for the medical microorganism examination work so that the bacteria identification/drug experimenting is more accurate, simpler, micro and rapid.

The invention provides a device that can be used in a precise tumor treatment method based on CTC circulating tumor cells. It includes the following steps: CTC circulating tumor cell isolation equipment, used to separate CTC circulating tumor cells from the added peripheral blood; CTC circulating tumor cell detection equipment, used to detect the separated CTC circulating tumor cells; CTC circulating tumor cells that can be closed Cell culture equipment is used to culture and proliferate isolated CTC circulating tumor cells in vitro; drug sensitivity testing equipment is used to conduct drug sensitivity experiments on cultured CTC circulating tumor cells. The present invention uses the patient's CTC circulating tumor cells to carry out in vitro drug sensitivity test, which has personalized and precise treatment effect for the patient; the method of parallel drug sensitivity test in the present invention can optimize a clinical drug regimen each time, so that tumor cells are always facing The attack on different types of drugs weakens the ability of tumors to adapt to drugs, which can avoid the problem of drug resistance caused by a single clinical drug.

The invention discloses application of 2,6-bis(2-benzimidazolyl) pyridine in preparation of a carbapenem-resistant pseudomonas aeruginosa infection drug. Through circular dichroism, fluorescent real-time quantitative PCR and other methods, it is found that 2, 6-bis (2-benzimidazolyl) pyridine can form a G-quadruplex structure with a core sequence of a MexA gene in pseudomonas aeruginosa, thereby inhibiting expression of the MexA gene. A susceptibility testing verifies that 2, 6-bis (2-benzimidazolyl) pyridine can reduce the drug resistance of carbapenem-resistant pseudomonas aeruginosa to meropenem. When the usage amount of the 2, 6-bis (2-benzimidazolyl) pyridine is 5 <mu>M, the minimum inhibitory concentration of the carbapenem-resistant pseudomonas aeruginosa strain can be reduced to 2<mu> g/ml, and the effect of treating carbapenem-resistant pseudomonas aeruginosa infection by using meropenem is achieved.

The invention relates to a fiber-optic gyroscopemagnetic susceptibilitytesting system. The system comprises a magnetic field generation device, a support, a vibration isolation platform, a power supply system, a gyroscope interface unit, a measurement and control computer and a direct-current stabilized power supply, wherein the magnetic field generation device is connectedwiththe direct-current stabilized power supply; thesupport is arranged in the magnetic field generation device, and a fiber-optic gyroscope is placed on the support; the vibration isolation platform is arranged at the bottom of the support; one end of the gyroscope interface unit is connected with thefiber-optic gyroscope, and the other end is connected with the measurement and control computer; the power supply system is connected with the gyroscope interface unit, the measurement and control computer and the direct-current stabilized power supplyrespectively; and the measurement and control computer is further connected onto the direct-current stabilized power supply. Thefiber-optic gyroscopemagnetic susceptibility testing system has the advantages of simple structure, capability of generating a three-dimensional magnetic field, accuracy in testing, conveniencein control and the like.

The present invention relates to a novel bioactivity testing structure for single cell tracking using a gelling agent and a bioactivity testing system including the testing structure. The present invention also relates to bioactivity testing, drug susceptibility testing, antibiotic screening, and diagnostic methods using the testing structure. The bioactivity testing structure of the present invention enables very rapid and simple drug susceptibility testing of bacteria, particularly Mycobacterium tuberculosis, drug screening, and bacterial diagnosis. Particularly, the use of the testing structure enables DST and diagnosis of bacteria only by pretreatment without the need to concentrate human sputum samples irrespective of inoculum effect, ensuring rapid, accurate, and simple testing compared to conventional tuberculosis diagnosis or DST systems. In addition, the testing structure of the present invention simultaneously enables the diagnosis and drug susceptibility testing of tuberculosis. Therefore, the present invention provides an effective alternative to the prior art.

The present invention is directed to the field of microbiology and in particular to compositions and methods for determining susceptibility of aerobic pathogens to antibiotics. The addition of adjuvants to the compositions of the invention stabilize the test medium and eliminates inconsistencies in susceptibility testing, most especially testing involving the tetracycline family of antibiotics.

Device for susceptibility testing of bacterial pathogens and vaccine strains in poultry with a microtiter plate comprising a plurality of wells and at least one well with a coating containing an antibiotic of a marker of a vaccine strain for the vaccination of poultry.

The invention discloses an enzyme linked immunosorbent assay instrument testing method for penicillium marneffei mycelia-phase in-vitro susceptibility testing. The light transmittance of a bacterium-containing diluent with an antibiotic medicinal liquid is tested by using an enzyme linked immunosorbent assay instrument in the penicillium marneffei mycelia-phase in-vitro susceptibility testing process. The densities are different in different bacterium growth situations, the light transmittances are also different, results are judged by using the enzyme linked immunosorbent assay instrument, apparent phenomena can be converted into values, and the operation can be relatively convenient and accurate; secondly, as an enzyme linked immunosorbent assay instrument pore plate is used, material consumption can be reduced; only a solution less than 1ml is needed in each pore, so that the amount of medicines is small, and waste can be greatly reduced; in addition, penicillium marneffei has infectivity, so that the pollution property can be further reduced because of the small use amount. Finally, normal growth of the penicillium marneffei can be not affected by the enzyme linked immunosorbent assay instrument, the operation is simple, convenient and rapid, and precise in-vitro susceptibility data results can be obtained.